Prospective analysis of parametric response map-derived MRI biomarkers: Identification of early and distinct glioma response patterns not predicted by standard radiographic assessment

Craig J. Galbán, Thomas L. Chenevert, Charles R. Meyer, Christina Tsien, Theodore S. Lawrence, Daniel A. Hamstra, Larry Junck, Pia C. Sundgren, Timothy D. Johnson, Stefanie Galbán, Judith S. Sebolt-Leopold, Alnawaz Rehemtulla, Brian D. Ross

    Research output: Contribution to journalArticlepeer-review

    72 Scopus citations

    Abstract

    Purpose: Currently, radiologic response of brain tumors is assessed according to the Macdonald criteria 10 weeks from the start of therapy. There exists a critical need to identify nonresponding patients early in the course of their therapy for consideration of alternative treatment strategies. Our study assessed the effectiveness of the parametric response map (PRM) imaging biomarker to provide for an earlier measure of patient survival prediction. Experimental Design: Forty-five high-grade glioma patients received concurrent chemoradiation. Quantitative MRI including apparent diffusion coefficient (ADC) and relative cerebral blood volume (rCBV) maps were acquired pretreatment and 3 weeks midtreatment on a prospective institutional-approved study. PRM, a voxel-by-voxel image analysis method, was evaluated as an early prognostic biomarker of overall survival. Clinical and conventional MR parameters were also evaluated. Results: Multivariate analysis showed that PRM ADC+ in combination with PRM rCBV- obtained at week 3 had a stronger correlation to 1-year and overall survival rates than any baseline clinical or treatment response imaging metric. The composite biomarker identified three distinct patient groups, nonresponders [median survival (MS) of 5.5 months, 95% CI: 4.4-6.6 months], partial responders (MS of 16 months, 95% CI: 8.6-23.4 months), and responders (MS has not yet been reached). Conclusions: Inclusion of PRM ADC+ and PRM rCBV- into a single imaging biomarker metric provided early identification of patients resistant to standard chemoradiation. In comparison to the current standard of assessment of response at 10 weeks (Macdonald criteria), the composite PRM biomarker potentially provides a useful opportunity for clinicians to identify patients who may benefit from alternative treatment strategies.

    Original languageEnglish
    Pages (from-to)4751-4760
    Number of pages10
    JournalClinical Cancer Research
    Volume17
    Issue number14
    DOIs
    StatePublished - Jul 15 2011

    Fingerprint

    Dive into the research topics of 'Prospective analysis of parametric response map-derived MRI biomarkers: Identification of early and distinct glioma response patterns not predicted by standard radiographic assessment'. Together they form a unique fingerprint.

    Cite this